WHO ICTRP trial
An Open-label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and…
CTIS2023-506285-31-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2023-506285-31-00 |
|---|---|
| Public title | An Open-label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors |
| Scientific title | - GO41596 |
| Primary sponsor | Genentech Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Yes Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Australia;Canada;United States;Brazil;Korea, Republic of;Netherlands;Belgium;Italy;Spain |
| Conditions | Locally Advanced or Metastatic Solid Tumors MedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104 MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class… |
| Registration date | Mar 19, 2024 |
| Target size | 275 |
| Secondary IDs | 2019-003986-16 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: